Belzutifan (Welireg) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
  • InChIKey: LOMMPXLFBTZENJ-ZACQAIPSSA-N
  • Mol. Mass: 383.35
  • ALogP: 3.29
  • ChEMBL Molecule:
    belzutifan  
More Chemistry

Pharmacology

Alternative names

pt2977

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (4)


 

Carcinoma, Renal Cell

Hemangioblastoma

Neuroendocrine Tumors

von Hippel-Lindau Disease

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Adenocarcinoma (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Healthy Volunteers (Phase 1)

Intestinal Neoplasms (Phase 2)

Kidney (Phase 2)

Kidney Failure, Chronic (Phase 1)

Kidney Neoplasms (Phase 2)

Liver Diseases (Phase 1)

Mutation (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

von Hippel-Lindau Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue